2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

  • Michael Heuser
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;
  • Sylvie D. Freeman
    Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom;
  • Gert J. Ossenkoppele
    Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
  • Francesco Buccisano
    Department of Biomedicine and Prevention, Hematology, University Tor Vergata, Rome, Italy;
  • Christopher S. Hourigan
    Laboratory of Myeloid Malignancy, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD;
  • Lok Lam Ngai
    Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
  • Jesse M. Tettero
    Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
  • Costa Bachas
    Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
  • Constance Baer
    MLL Munich Leukemia Laboratory, Munich, Germany;
  • Marie-Christine Béné
    Department of Hematology and Biology, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France;
  • Veit Bücklein
    Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany;
  • Anna Czyz
    Department of Hematology, Blood Neoplasms, and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland;
  • Barbara Denys
    Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University;
  • Richard Dillon
    Department of Medical and Molecular Genetics, King’s College, London, United Kingdom;
  • Michaela Feuring-Buske
    Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
  • Monica L. Guzman
    Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY;
  • Torsten Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany;
  • Lina Han
    Department of Leukemia and
  • Julia K. Herzig
    Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
  • Jeffrey L. Jorgensen
    The Department of Hematopathology, MD Anderson Cancer Center, Houston, TX;
  • Wolfgang Kern
    MLL Munich Leukemia Laboratory, Munich, Germany;
  • Marina Y. Konopleva
    Department of Leukemia and
  • Francis Lacombe
    Hematology Biology, Flow Cytometry, Bordeaux University Hospital, Pessac, France;
  • Marta Libura
    Medical University of Warsaw, Warsaw, Poland;
  • Agata Majchrzak
    Department of Experimental Hematology, Copernicus Memorial Hospital, Lodz, Poland;
  • Luca Maurillo
    Department of Biomedicine and Prevention, Hematology, University Tor Vergata, Rome, Italy;
  • Yishai Ofran
    Department of Hematology, Shaare Zedek Medical Center Faculty of Medicine Hebrew University, Jerusalem Israel;
  • Jan Philippe
    Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University;
  • Adriana Plesa
    Department of Hematology Laboratory, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France;
  • Claude Preudhomme
    Laboratory of Hematology, CHU Université de Lille, Lille, France;
  • Farhad Ravandi
    Department of Leukemia and
  • Christophe Roumier
    Laboratory of Hematology, CHU Université de Lille, Lille, France;
  • Marion Subklewe
    Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany;
  • Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;
  • Arjan A. van de Loosdrecht
    Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;
  • Bert A. van der Reijden
    Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands;
  • Adriano Venditti
    Department of Biomedicine and Prevention, Hematology, University Tor Vergata, Rome, Italy;
  • Agnieszka Wierzbowska
    Department of Hematology, Medical University of Lodz, Lodz, Poland;
  • Peter J. M. Valk
    Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands;
  • Brent L. Wood
    Department of Hematopathology, Children's Hospital Los Angeles, CA;
  • Roland B. Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
  • Christian Thiede
    Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany; and
  • Konstanze Döhner
    Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
  • Gail J. Roboz
    Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY;
  • Jacqueline Cloos
    Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;

抄録

<jats:title>Abstract</jats:title><jats:p>Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD recommendations based on significant developments in the field. New and revised recommendations were established during in-person and online meetings, and a 2-stage Delphi poll was conducted to optimize consensus. All recommendations are graded by levels of evidence and agreement. Major changes include technical specifications for next-generation sequencing-based MRD testing and integrative assessments of MRD irrespective of technology. Other topics include use of MRD as a prognostic and surrogate end point for drug testing; selection of the technique, material, and appropriate time points for MRD assessment; and clinical implications of MRD assessment. In addition to technical recommendations for flow- and molecular-MRD analysis, we provide MRD thresholds and define MRD response, and detail how MRD results should be reported and combined if several techniques are used. MRD assessment in AML is complex and clinically relevant, and standardized approaches to application, interpretation, technical conduct, and reporting are of critical importance.</jats:p>

収録刊行物

  • Blood

    Blood 138 (26), 2753-2767, 2021-12-30

    American Society of Hematology

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ